Publications by authors named "Shimon Korish"
Background: Iberdomide, a cereblon modulator, promotes degradation of transcription factors Ikaros and Aiolos.
Objective: Evaluate iberdomide efficacy and safety in cutaneous lupus erythematosus (CLE) in a phase 2 study.
Methods: Patients were randomized (2:2:1:2) to iberdomide 0.
Achieving a good outcome for a person with Psoriatic Arthritis (PsA) is made difficult by late diagnosis, heterogenous clinical disease expression and in many cases, failure to adequately suppress inflammatory disease features. Single-centre studies have certainly contributed to our understanding of disease pathogenesis, but to adequately address the major areas of unmet need, multi-partner, collaborative research programmes are now required. HIPPOCRATES is a 5-year, Innovative Medicines Initiative (IMI) programme which includes 17 European academic centres experienced in PsA research, 5 pharmaceutical industry partners, 3 small-/medium-sized industry partners and 2 patient-representative organizations.
View Article and Find Full Text PDFObjectives: Iberdomide is a high-affinity cereblon ligand that promotes proteasomal degradation of transcription factors Ikaros () and Aiolos (). Pharmacodynamics and pharmacokinetics of oral iberdomide were evaluated in a phase 2b study of patients with active systemic lupus erythematosus (SLE).
Methods: Adults with autoantibody-positive SLE were randomised to placebo (n=83) or once daily iberdomide 0.
Article Synopsis
- Iberdomide is being tested as a treatment for systemic lupus erythematosus (SLE) by promoting the degradation of key transcription factors related to immune response.
- In a phase 2 trial, 288 patients were randomly assigned to receive iberdomide in different doses or a placebo for 24 weeks, evaluating the effectiveness through a specific index called SLE Responder Index (SRI-4).
- Results showed that 54% of patients taking the highest dose of iberdomide achieved a significant clinical response compared to 35% in the placebo group, though side effects mainly included infections and low white blood cell counts.
Objective: To evaluate safety, pharmacokinetics, pharmacodynamics and efficacy of iberdomide in patients with SLE. Iberdomide is a high-affinity cereblon ligand that targets the hematopoietic transcription factors Ikaros and Aiolos for proteasomal degradation.
Methods: A 12-week, multicentre, double-blind, placebo-controlled, dose-escalation study in active SLE was followed by a 2-year, open-label active treatment extension phase (ATEP) (NCT02185040).
Introduction: Spebrutinib (CC-292) is an orally administered, covalent, small-molecule inhibitor of Bruton's tyrosine kinase (BTK), part of the B-cell and Fc receptor signaling pathways. This study evaluated spebrutinib pharmacology and mechanism of action over a 4-week treatment period in patients with active rheumatoid arthritis (RA).
Methods: Primary human B cells, T cells, natural killer cells, macrophages, dendritic cells, basophils, and osteoclasts were treated with spebrutinib in vitro.
Objective: To evaluate the safety and efficacy of pomalidomide (POM) on forced vital capacity (FVC), modified Rodnan skin score (mRSS), and gastrointestinal (GI) symptomatology over 52 weeks of treatment in patients with interstitial lung disease due to systemic sclerosis (SSc).
Methods: Twenty-three adult patients diagnosed with SSc were randomized 1:1 POM:placebo (PBO).
Results: Mean change at Week 52 from baseline in predicted FVC% -5.